Elias Obeid
Medical Oncology · Philadelphia, PANPI 1194760843
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $26,894 of the $37,945 with a category attached, or 70.9%. 13 manufacturers reported payments, led by Pfizer at 32.6% of the total. Reporting peaked in 2022 at $18,453 and has fallen 91.8% since, to $1,517 in 2025.
Across 65 payments — averaging $583.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$12K
- Gilead$8K
- GE HealthCare$4K
- Novartis$4K
- AstraZeneca$3K
- Puma Biotechnology, Inc.$3K
- plus $4K from 7 others
Across 92 payments — averaging $33,893 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$3.1M
- Pfizer$4K
What the payments were for
- Consulting fees$26,89471%
- Speaking & faculty fees$6,93018%
- Travel & lodging$1,2253%
- Food & beverage$1,5754%
- Education$250%
- Other$1,2963%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 11 | $12,358 |
| Gilead | 10 | $7,695 |
| GE HealthCare | 1 | $3,738 |
| Novartis | 15 | $3,659 |
| AstraZeneca | 4 | $3,425 |
| Puma Biotechnology, Inc. | 5 | $2,959 |
| GSK | 1 | $1,950 |
| Daiichi Sankyo Inc. | 7 | $1,556 |
| Genentech, Inc. | 5 | $477 |
| Tempus AI, Inc | 3 | $84 |
| Siemens Medical Solutions USA, Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,945 in reported general payments places this provider in the 80th percentile of 238 medical oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 18 | $2,228 |
| Exemestane | 13 | $1,847 |
| Anastrozole | 74 | $1,694 |
| Prochlorperazine Maleate | 15 | $183 |
| Tamoxifen Citrate | 21 | $142 |
| Dexamethasone | 12 | $66 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Philadelphia
- Carl JunePhiladelphia$9M
- Shayma KazmiPhiladelphia$619K
- Marcia BrosePhiladelphia$260K
- Adam CohenPhiladelphia$239K
- Daniel HallerPhiladelphia$227K
- Edith MitchellPhiladelphia$220K
- Elizabeth PlimackPhiladelphia$190K
- Alexander PerlPhiladelphia$176K
- Martin EdelmanPhiladelphia$157K
- Jean-Pierre IssaPhiladelphia$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.